Lasmiditan + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Migraine
Conditions
Migraine
Trial Timeline
Jun 24, 2019 → Jul 8, 2021
NCT ID
NCT03670810About Lasmiditan + Placebo
Lasmiditan + Placebo is a phase 3 stage product being developed by Eli Lilly for Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT03670810. Target conditions include Migraine.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04396236 | Phase 3 | Terminated |
| NCT04081324 | Phase 1 | Completed |
| NCT03670810 | Phase 3 | Completed |
| NCT03962738 | Phase 2 | Completed |
| NCT03579940 | Phase 1 | Completed |
| NCT03406260 | Phase 1 | Completed |
| NCT03182920 | Phase 1 | Completed |
| NCT00883051 | Phase 2 | Completed |
| NCT00384774 | Phase 2 | Completed |
Competing Products
20 competing products in Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABP-450 | AEON Biopharma | Phase 2 | 44 |
| Placebo + LY2300559 | Eli Lilly | Phase 2 | 52 |
| lasmiditan 200 mg + Sumatriptan + matching placebo | Eli Lilly | Phase 1 | 33 |
| ABP-450 + Placebo | AEON Biopharma | Phase 2 | 44 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 52 |
| Ketorolac + Prochlorperazine + Diphenhydramine | Assertio Holdings | Phase 2 | 44 |
| Galcanezumab + Erenumab | Eli Lilly | Approved | 85 |
| Aricept (donepezil hydrochloride) | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| Galcanezumab + Rimegepant + Placebo + Placebo | Eli Lilly | Approved | 85 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 52 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Lasmiditan | Eli Lilly | Phase 3 | 77 |
| Galcanezumab Prefilled Syringe + Placebo | Eli Lilly | Phase 2 | 52 |
| Emgality 120 MG in 1 ML Prefilled Syringe | Eli Lilly | Approved | 85 |
| Galcanezumab | Eli Lilly | Pre-clinical | 23 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2590443 + Placebo injection + Sumatriptan + Placebo capsule | Eli Lilly | Phase 2 | 52 |